Navigation Links
Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
Date:9/23/2009

X BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for Zerenex (ferric citrate), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Liti
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
2. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
7. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
10. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
11. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... GeoInvesting.com, we have been tracking Tianyin Pharmaceuticals (NYSE Amex: ... hang up had been with the potential dilution from ... income guidance of $11.3 million represents a 43.0% increase ... million, the increase in shares poses some uncertainty regarding ... the share price and the Treasury method of accounting ...
(Date:12/14/2009)... HELSINKI, Dec. 14 Cancer patients in ... with the introduction of RapidArc® radiotherapy technology from ... at the only private radiotherapy clinic in the ... are using this fast and precise form of ... and cancers of the abdomen and prostate. ,, ...
(Date:12/14/2009)... When staff from a leading orthopaedic ... difficult to adjust and uncomfortable cubital tunnel splints ... Inc. (PPI) to develop a superior alternative. ... for nearly five decades, responded with the revolutionary ... it announced today. Simple to fit and ...
Breaking Medicine Technology:GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3New Cubital Tunnel Splint Specially Designed for Comfort and Less Cumbersome Fit 2Commonwealth Fund Case Study Points to Continuous Innovation at Group Health Cooperative 4643 1Commonwealth Fund Case Study Points to Continuous Innovation at Group Health Cooperative 4643 2Commonwealth Fund Case Study Points to Continuous Innovation at Group Health Cooperative 4643 3MarketArt to Provide APCO With Rapid Response at World 26apos 3Bs Largest Public Safety Communications Event 49962 1MarketArt to Provide APCO With Rapid Response at World 26apos 3Bs Largest Public Safety Communications Event 49962 2MarketArt to Provide APCO With Rapid Response at World 26apos 3Bs Largest Public Safety Communications Event 49962 3Milestone Scientific Expands Global Sales Strategy to Enhance Penetration of International Dental Markets 49960 1Milestone Scientific Expands Global Sales Strategy to Enhance Penetration of International Dental Markets 49960 2Milestone Scientific Expands Global Sales Strategy to Enhance Penetration of International Dental Markets 49960 3
(Date:12/14/2009)... Twelve variants seen in one gene, researchers say , , ... pinpointed a dozen genetic variants in a single gene ... University School of Medicine in St. Louis analyzed the ... heart failure, and identified 129 variants in four genes ... of 1,117 whites with heart failure and 625 healthy ...
(Date:12/14/2009)... government controlled health care, before moving to the U.S. to practice ... his new book, Health Reform: The End of the American Revolution?, ... its threat to real health care! , ... (PRWEB) ... from Minnesota, warns Americans not to sell out their liberty for ...
(Date:12/14/2009)... CT procedures vary widely and are higher than generally thought, raising ... led by University of California, San Francisco (UCSF) imaging ... ... 2009 -- Radiation doses from common CT procedures vary widely and ... cancer, according to a new study led by University of ...
(Date:12/14/2009)... Pasierb, President ,, NEW YORK, Dec. 14 ... the Future study (MTF) -- the largest survey on ... 12th graders -- underscores that teens, intentional abuse of ... a cause for concern, with an alarming number of ... relatives. ,, Teen Abuse of Medication ...
(Date:12/14/2009)... 14 Grubb & Ellis Healthcare REIT II, Inc. ... daily distribution to stockholders of record as of the close ... Jan. 1, 2010 and ending on Feb. 28, 2010. ... the calendar year and will be equal to an annualized ... $10.00 per share. These distributions will be aggregated and ...
Breaking Medicine News(10 mins):Health News:Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America 2Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3
... the number of people with vision loss from age-related macular ... is caused by a deterioration of the retina, is the ... of years ago, researchers conducted a large study to see ... beta carotene, along with zinc oxide or zinc alone could ...
... symptoms women experience before having a heart attack may ... experience. ,Researchers interviewed more than 500 women who ... different medical sites. The average age of the women ... their symptoms before their heart attack. They also took ...
... premature birth are a mystery in nearly half of the ... stress, infections, high blood pressure, //bleeding or stretching of the ... experts say fertility troubles could explain part of the problem. ... 37 weeks of pregnancy -- is a major public health ...
... viral cold are common in preschoolers. These attacks are ... school age. //The current recommendation is that parents administer ... But whether or not the steroids are effective is ... steroids was no more effective than placebo in reducing ...
... a major improvement for HIV patients in less-developed countries. The ... HIV medication.// ,HIV patients are often put on antiretroviral ... on the medication, tests to determine the CD4 cell count ... for more intensive treatment while a high CD4 cell count ...
... have a new tool to help acne patients. A new ... sufferers. //This is important because this skin disease can lead ... even suicide. ,Doctors from London recruited 41 adults with ... one treatment of the pulsed-dye laser. The other 10 served ...
Other Medicine News:Health News:Women who conceive after a year have a higher chance of giving birth prematurely 2
Spectrum Dynamics empowers Nuclear Imaging with the SmartR Technology,of the D-SPECT Cardiac Imaging System. The D-SPECT is powered by BroadView Technology to provide unprecedented throughput, whil...
For immediate disabling...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
... A valuable new tool for the ... greater dynamic range and shows less ... at the same degree of reproducibility ... been shown to correlate with the ...
Medicine Products: